Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Albumin 5%, Human Albumin 5%, Albutein 5%
Albumin · 5 trials · 3 indications
Time to one-year transplant-free survival was calculated as earlier of \[(date of liver transplantation or date of death) - randomization date + 1\] for participants who died or had liver transplant within the analysis period of 361 days. Participants who neither died nor had liver transplant within analysis period had their time to event censored at earlier of date of last contact or cut-off date. Participants who terminated early for reasons other than death were followed up at months 3, 6, and 12 to collect information on liver transplantation and death, these events if reported by cut-off Day 361, were considered for the endpoint. The percentage of participants with events are presented. The percentage of participants was calculated as \[(participants with an event up to the analysis cut-off Day 361) / (number of participants in the ITT group)\].
ADAS-Cog total score as a change from baseline to 14 months The ADAS-Cog Scale is a questionnaire that assesses cognitive performance in 12 different domains. The domains are: word recall, commands, constructional praxis, delayed word-recall task, naming objects/figures, ideational praxis, orientation, word recognition, remembering test instructions, comprehension, word finding difficulty, and spoken language ability. The total score ranges from 0-80 where a higher score indicates more cognitive impairment.
ADCS-ADL total score as a change from baseline to 14 months The ADCS-ADL comprises 23 questions covering a wide array of activities of daily living. Many of the activities begin with an assessment of whether that activity is relevant and then, if yes, follow with an assessment of the difficulty. The total score over all activities ranges from 0-78 where a higher score indicates more autonomy (better outcome).
The ALSFRS-R includes 12 questions to assess the self-sufficiency of participants in 3 sub-domains: bulbar function (questions 1-3), fine and gross motor function (questions 4-9), and respiratory function (question 10-12). Aspects of nourishment, personal care, personal autonomy, and communication were also evaluated. Each task was graded on a five-point scale from 0 (incapable) to 4 (normal ability), with total score range from 0 (worst) to 48 (best). A positive change from Baseline indicates improvement.
The FVC measured the volume of air that can forcibly be exhaled through a spirometer after a full inspiration. It was expressed in a percentage of actual FVC over the expected FVC result in the general population, calculated as: Percent predicted FVC (in %) = \[(observed FVC in liters)/(predicted FVC in liters)\]\*100.
Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) includes 12 questions classified into 3 subdomains: bulbar function (3 questions), fine and gross motor skills (6 questions), and respiratory function (3 questions) to assess the level self sufficiency. Each task was graded according to a 5-point scale from 0 (incapable) to 4 (normal ability) with a total score from 0 (worst) to 48 (best).
Change in levels of Aβ1-42 in CSF in the period between baseline lumbar puncture (before the start of treatment) and lumbar puncture immediately after the end of the last plasma exchange (whenever this may be). Separate assays of Aβ1-42 were performed with Innotest and The Genetics Company commercial kits.
| Arm | Type | Description |
|---|---|---|
| SMT + Albutein 20% | EXPERIMENTAL | Participants received Albutein 20%, at a dose of 1.5 grams/kilograms (g/kg), based on their body weight (maximum 100 grams per participant), as an intravenous (IV) infusion on Day 1, followed by the same dose of Albutein 20% every 10±2 days along with standard medical treatment (SMT) administered as per institution standards for the management of decompensated cirrhosis up to 12 months. |
| SMT | ACTIVE_COMPARATOR | Participants received SMT up to 12 months as per institution standards for the management of decompensated cirrhosis. |
| High Albumin + Immunoglobulin | EXPERIMENTAL | Therapeutic plasma exchange with albumin 5% (intensive treatment period) + Low volume plasma exchange with high dose of albumin 20% or immunoglobulin 5% (maintenance treatment period) |
| Low Albumin + Immunoglobulin | EXPERIMENTAL | Therapeutic plasma exchange with albumin 5% (intensive treatment period) + Low volume plasma exchange with low dose of albumin 20% or immunoglobulin 5% (maintenance treatment period) |
| Low Albumin | EXPERIMENTAL | Therapeutic plasma exchange with albumin 5% (intensive treatment period) + Low volume plasma exchange with low dose of albumin 20% (maintenance treatment period) |
| Control (sham) group | NO_INTERVENTION | Simulated plasma exchange procedure |
| Albutein 5% | EXPERIMENTAL | Plasma exchanges (PEs) with albutein 5% as a replacement solution during an intensive treatment phase of two PEs per week over 3 weeks followed by maintenance treatment phase of weekly PE for 21 weeks. The dose of albutein 5% for replacement following plasma removal was calculated based on gender, weight, and the hematocrit of the participant. |
| Albumin | EXPERIMENTAL | Plasma exchange with Albumin |
| Control | SHAM_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Albutein 20% | DRUG | Injectable solution |
| SMT | OTHER | Participants received SMT according to institution standards for the management of decompensated cirrhosis. |
| Albumin 5% | BIOLOGICAL | Therapeutic plasma exchange with human albumin 5% |
| Albumin 20% | BIOLOGICAL | Low volume plasma exchange with human albumin 5% |
| Immunoglobulin | BIOLOGICAL | Intravenous human immunoglobulin 5% |
| Albutein 5% | BIOLOGICAL | Albutein is manufactured from human plasma. The dose of Albutein 5% for replacement following plasma removal will be calculated based on gender, weight, and the hematocrit of the participant. |
| Plasma Exchange | PROCEDURE | Plasma Exchange will be performed using albutein 5% as the replacement solution. |
| Albumin | BIOLOGICAL | 27 plasma exchange procedures using Albumin 5% (estimated 3000 mL per plasma exchange) as replacement solution: * three weeks of intensive treatment with two plasma exchanges per week * twenty-one weeks of maintenance treatment with one weekly plasma exchange |
| Control | OTHER | Control group followed the same schedule; however, they did not undergo plasma replacement (it was subjected to simulated plasma replacements) |
Inclusion Criteria: * Male or female participants ≥18 years of age. * Participants with diagnosis of liver cirrhosis (based on clinical, laboratory, endoscopic, and ultrasonographic features or on histology). * Participants who have been hospitalized for acute decompensation of liver cirrhosis with...
Top 20 of 31 competitors
Albumin 5% has been studied in clinical trials for Alzheimer's disease and amyotrophic lateral sclerosis, also known as ALS. It is a plasma-derived human albumin product developed by Grifols, S.A. under the ticker GRFS. Both programs are Phase 2 and the trials have been completed.
Albumin 5% is made by Grifols, S.A., which trades under the ticker GRFS. Grifols is the developer associated with the clinical programs studying this human albumin product in Alzheimer's disease and amyotrophic lateral sclerosis.
Albumin 5% is in Phase 2 development. It is investigational and is not approved for Alzheimer's disease or amyotrophic lateral sclerosis. Two Phase 2 trials have been completed, and no trials are currently active.
Albumin 5% has been studied in two completed Phase 2 trials. NCT01561053 evaluated albumin and immunoglobulin in Alzheimer's disease across the United States and Spain with 347 participants. NCT02479802 evaluated plasma exchange with albumin in amyotrophic lateral sclerosis in Spain with 13 participants.
Yes. Albumin 5% is also known as Albumin, Albumin (Human) 20% United States Pharmacopeia, Albumin 20% United States Pharmacopeia, Albumin (Human) 25% United States Pharmacopeia, and Albumin 25% United States Pharmacopeia. These names refer to the same human albumin product.
The Albumin 5% clinical program enrolled 347 participants in total. The Alzheimer's disease trial NCT01561053 accounted for 347 participants, while the amyotrophic lateral sclerosis trial NCT02479802 enrolled 13 participants. Both were randomized, double-blind Phase 2 studies.